Special Issue "Biomarkers of Oral Cancer"
Deadline for manuscript submissions: closed (30 November 2020) | Viewed by 31136
Oral cancer is the 11th most common malignancy in the world, with 354,864 new cases and 177,384 deaths worldwide (GLOBOCAN, 2018) The highest incidence of these cancers has mainly been reported in South and Southeast Asia and some countries in southern Europe.
The most important risk factors for oral cancer development are tobacco use and extensive alcohol consumption. Moreover, infection with oncogenic types of human papillomavirus (HPV) has been identified as a significant risk factor for a subset of oral cancer.
The main reasons for failure in oral cancer treatment, and the strongest adverse factors for prognosis, are the spread to the regional lymph nodes and early development of local recurrence or second primary tumors. Modern head and neck oncology can offer a plethora of treatment modalities including surgical resection with reconstructive options, radiotherapy (including proton therapy), conventional and targeted systemic treatment, and also, as of late, immunotherapy. The success rates of treatments can significantly vary between particular patients. Thus, one of the biggest future challenges is to tailor multidisciplinary treatments such that they are based not only on clinical assessment of disease advancement determined by stage, but also on the biological factors of the tumor.
Advances in genetics and molecular biology have improved our knowledge of cellular mechanisms, which provide insights into the pathophysiological processes that turn healthy epithelial cells into cancer. Potential biomarkers and therapeutic targets can be investigated to identify genetic signatures that could potentially be used for early diagnosis, treatment personalization, and finally, determination of prognosis for individual patients.
Prof. Dr. Paweł Golusiński
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Oral cancer
- Head and neck squamous cell carcinoma
- Molecular diagnostics
- Risk factors
- Treatment strategies